Compare Nippon Shinyaku Co., Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 379,147 Million (Mid Cap)
8.00
NA
0.00%
-0.25
12.29%
1.46
Revenue and Profits:
Net Sales:
47,488 Million
(Quarterly Results - Dec 2025)
Net Profit:
10,088 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.86%
0%
-10.86%
6 Months
55.73%
0%
55.73%
1 Year
29.67%
0%
29.67%
2 Years
10.85%
0%
10.85%
3 Years
-12.67%
0%
-12.67%
4 Years
-40.27%
0%
-40.27%
5 Years
-34.34%
0%
-34.34%
Nippon Shinyaku Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.56%
EBIT Growth (5y)
11.15%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.22
Sales to Capital Employed (avg)
0.66
Tax Ratio
9.89%
Dividend Payout Ratio
25.65%
Pledged Shares
0
Institutional Holding
3.50%
ROCE (avg)
22.88%
ROE (avg)
12.48%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
1.00
EV to EBIT
5.23
EV to EBITDA
4.49
EV to Capital Employed
1.00
EV to Sales
1.20
PEG Ratio
0.29
Dividend Yield
0.01%
ROCE (Latest)
19.04%
ROE (Latest)
13.18%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Mar 2015
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
47,488.00
40,101.00
18.42%
Operating Profit (PBDIT) excl Other Income
12,726.00
10,251.00
24.14%
Interest
19.00
55.00
-65.45%
Exceptional Items
0.00
0.00
Consolidate Net Profit
10,088.00
7,506.00
34.40%
Operating Profit Margin (Excl OI)
233.10%
214.70%
1.84%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 18.42% vs 1.40% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 34.40% vs -9.08% in Sep 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
160,232.00
148,255.00
8.08%
Operating Profit (PBDIT) excl Other Income
42,779.00
36,409.00
17.50%
Interest
102.00
57.00
78.95%
Exceptional Items
-892.00
-994.00
10.26%
Consolidate Net Profit
32,560.00
25,853.00
25.94%
Operating Profit Margin (Excl OI)
229.40%
211.70%
1.77%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 8.08% vs 2.83% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 25.94% vs 13.30% in Mar 2024
About Nippon Shinyaku Co., Ltd. 
Nippon Shinyaku Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






